Taking It For Granted - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Taking It For Granted

Pharmaceutical Technology Europe
Volume 23, Issue 10

Rich Whitworth
As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.

It is very easy to take for granted the things we use daily, especially in the (over?) developed world where we think nothing of supermarket shelves being (over?) stocked with exotic fruit, bread mountains and rivers of wine from around the globe. But in every instance, there is a company, a process and a horde of employees behind the seemingly simple task of making something "available" and maintaining that all important supply chain. And so it is with the pharma industry.

On a recent trip to a sterile manufacturing facility in Glasgow, I was once again learning something new. I had not previously considered the processes and scale of the equipment necessary to produce even the simplest of solutions (buffers!) required in the volume and, more importantly, the quality required by the biopharmaceutical industry. The water-for-injection plant was an amazing feat of engineering in itself and the house-size mixing tanks put figures like 10000 litres into real perspective.

More often than not, the simplicity of the material belies its manufacturing process and it becomes a commodity. Perhaps to such a point, that we stop questioning its origin at all. I think we all agree that quality and patient safety must be at the top of everyone's agenda, but in the face of increasingly fierce competition and a never ending quest by customers for lower costs, perhaps something, somewhere has got to give?

On a completely different topic, several people have asked me if the crossword on the front cover of our September issue "works" — it does indeed. And so as not to take for granted the sense of reader anticipation in the air, the answers are included below.

I very much look forward to meeting some of you at CPhI 2011 this month; feel free to stop by at booth number 51F53 to meet the PTE team.

Best wishes,
Rich Whitworth

1. PSD 6. Generic 10. Isolator 13. TSA 14. Bioconjugate

Down 2. Synthesis 3. Crystallise 4. Precipitation 5. Microdose 7. Cytotoxic 8. Blockbuster 9. Cytostatic 11. MAB 12. HPAPI


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here